Your Partner in Innovative Cancer Care

Together with you – the healthcare professional in practice or training – we’re finding the answers, insights, and treatment options that people with cancer deserve.

How to Refer a Patient

Memorial Sloan Kettering’s Patient Access Service is an easy way for doctors to refer a patient to a Memorial Sloan Kettering specialist. Find helpful phone numbers and other resources.


Our renowned fellowship programs prepare doctors for leadership roles in the care of people with cancer around the world.

Learn more

Clinical Trials

At any one time Memorial Sloan Kettering is running hundreds of clinical trials. Through these studies we can improve care for people with all types of cancer. Browse the MSK clinical trials that are currently enrolling new patients.

Prediction Tools

MSK’s researchers have developed prediction tools known as nomograms. These tests can help people with cancer and doctors make treatment decisions. The tools can be used to predict cancer outcomes. Nomograms also assess an individual’s risk based on the characteristics of their specific disease.

Clinical Updates & Insights

Get the latest updates from MSK doctors. Read about new treatments, clinical trials, and innovations in detecting and treating many cancers.

Clinical Update

Chemotherapy Reduces Seizures in Low-Grade Oligodendroglioma

Temozolomide chemotherapy reduced seizures in 90 percent of patients with World Health Organization (WHO) grade 2 oligodendroglioma and tumor-related epilepsy.

Dr. Anthony F. Yu and patient

Clinical Update

Minimizing Cardiotoxicities of Contemporary Breast Cancer Treatments

In our recently published review paper we provide a comprehensive update on the cardiotoxicities associated with contemporary breast cancer treatment and the latest strategies for their prevention, detection, and management.

Intensity-modulated radiation therapy (IMRT)

Clinical Update

Less Risk of Femoral Fracture with Intensity-Modulated Radiation Therapy for Thigh and Groin Sarcoma

Intensity-modulated radiation therapy (IMRT) confers a lower risk of femoral fracture in patients with primary soft tissue sarcoma of the thigh or groin, despite a higher dose of radiation to the target volume compared to conventional radiation.